Drug intelligence / Profile preview

COVIDIOL

Development stage: Preclinical
Lead developer: Cannabis Bioscience International
Modality: Small Molecules
Administration: Oral

Overview

**COVIDIOL** is an oral, preclinical cannabinoid-based capsule program from Cannabis Bioscience International Holdings for COVID-19. The product is described as containing the phytocannabinoids cannabidiol and cannabigerol and is intended to modulate immune responses associated with SARS-CoV-2 infection. No product-specific molecular targets, dose, clinical trial registration, or clinical efficacy data were identified in the supplied pipeline information.

Other names: CovidiolCovidiol Capsules

Beyond the preview

Go deeper on COVIDIOL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVIDIOL.

Explore the full profile